NCT01861730: Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants |
|
|
| Completed | 1/2 | 243 | RoW | AERAS-404, H4, Placebo, Tris buffered saline | Aeras, Statens Serum Institut, Sanofi Pasteur, a Sanofi Company, National Institute of Allergy and Infectious Diseases (NIAID), International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Tuberculosis | 12/17 | 12/17 | | |
